This healthcare stock engaged in providing primary to quaternary care services through hospitals, clinics, pharmacies, and diagnostic labs across GCC states and India, in focus after the company planning to invest Rs. 850 crore over the next three years in Kerala.
Stock Price Movement:
With a market capitalization of Rs. 20,215.29 crores, the shares of Aster DM Healthcare Limited were currently trading at Rs. 405 per equity share, down nearly around 2.36 percent from its previous day’s close price of Rs. 414.80.
What Happened:
Aster DM Healthcare announced on Friday that it will invest Rs 850 crore over the next three years in Kerala to improve infrastructure, medical services, and job opportunities. This follows the Rs 500 crore already invested in the state over the past three years.
Currently, Aster operates seven hospitals in Kerala with 2,635 beds, contributing to 53 percent of its India revenue. The company plans to increase its total number of beds in Kerala to 3,453 by FY27.
Management Commentary:
Azad Moopen, Founder and Chairman of Aster DM Healthcare, said at the Invest Kerala Global Summit 2025, “We plan to invest an additional Rs. 850 crore in the next three years to further strengthen Kerala’s healthcare landscape. Our expansion plans reflect our unwavering belief in Kerala’s potential as a leader in healthcare innovation and accessibility.”
Anoop Moopen, Director of Aster DM Healthcare, added, “With our expansion plans, we anticipate creating an additional 4,200 jobs, further strengthening Kerala’s healthcare workforce and economy.”
Business Operation:
The company has a strong presence across 15 cities in 5 states, operating 19 hospitals with a total capacity of 5,128 beds. It also runs 13 clinics, 254 labs and patient experience centers (PECs), and 203 pharmacies.
Recent quarter results:
Aster DM Healthcare Limited’s revenue has increased from Rs. 955 crore in Q3 FY24 to Rs. 1,050 crore in Q3 FY25, which has grown by 9.95 percent. The net profit has dropped by 69.38 percent from Rs. 209 crore in Q3 FY24 to Rs. 64 crore in Q3 FY25.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses
